Dataset Open Access

Purification of HTT Q23 and Q54 from EXPI293F for mass spectrometry analysis 2019/09/30

Harding, Rachel; Hutchinson, Ashley; Seitova, Alma; Arrowsmith, Cheryl; Edwards, Aled

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Harding, Rachel</dc:creator>
  <dc:creator>Hutchinson, Ashley</dc:creator>
  <dc:creator>Seitova, Alma</dc:creator>
  <dc:creator>Arrowsmith, Cheryl</dc:creator>
  <dc:creator>Edwards, Aled</dc:creator>
  <dc:description>Project: Biophysical investigation of purified HTT protein samples

Experiment: Purification of Q23 and Q54 HTT from EXPI293F

Date completed:­ 2019/09/30

Rationale: Purify HTT Q23 and Q54 for mass spectrometry analysis</dc:description>
  <dc:description>Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.</dc:description>
  <dc:subject>huntington's disease</dc:subject>
  <dc:subject>protein purification</dc:subject>
  <dc:subject>mass spectrometry</dc:subject>
  <dc:title>Purification of HTT Q23 and Q54 from EXPI293F for mass spectrometry analysis 2019/09/30</dc:title>
All versions This version
Views 3838
Downloads 2424
Data volume 3.2 MB3.2 MB
Unique views 3535
Unique downloads 1818


Cite as